Lubin V, Shojai R, Darmon P, Cosson E
Maternité, Clinique de l'Étoile, 13100 Aix-en-Provence, France.
Maternité, Clinique de l'Étoile, 13100 Aix-en-Provence, France.
Diabetes Metab. 2016 Jun;42(3):192-5. doi: 10.1016/j.diabet.2016.01.005.
This study assessed whether myoinositol might be a first-line medical treatment for gestational diabetes mellitus (GDM).
For 12 months, women with GDM not controlled by diet (n=32) were prospectively treated with myoinositol 1200mg and folic acid 400μg/day, while consecutive women (n=28) with insulin-requiring GDM treated during the previous year at our centre constituted the control group. Baseline characteristics and care were similar in both groups.
Insulin was required in eight women (25%) in the myoinositol group who, compared with the 24 who did not need insulin, were older (37±5 vs. 32±5 years, respectively; P=0.018) and had a larger percentage of high self-monitored glucose values (45±8% vs. 32±14%; P<0.0001) during the week prior to the introduction of myoinositol treatment. All of the women had similar pregnancy outcomes regardless of their GDM management, although less labour induction was required in the myoinositol group (OR: 0.22 [0.07-0.65]), which had no side effects.
This pilot study suggests that myoinositol may be a safe first-line medical treatment for uncontrolled GDM.
本研究评估了肌醇是否可能作为妊娠期糖尿病（GDM）的一线药物治疗。
连续12个月，对32例饮食控制不佳的GDM女性前瞻性给予每日1200mg肌醇和400μg叶酸治疗，而前一年在本中心接受胰岛素治疗的连续28例GDM女性作为对照组。两组的基线特征和护理情况相似。
肌醇组有8名女性（25%）需要胰岛素治疗，与24名不需要胰岛素治疗的女性相比，她们年龄更大（分别为37±5岁和32±5岁；P=0.018），且在开始肌醇治疗前一周自我监测的高血糖值百分比更高（45±8%对32±14%；P<0.0001）。所有女性无论其GDM管理方式如何，妊娠结局相似，尽管肌醇组需要引产的情况较少（比值比：0.22[0.07-0.65]），且无副作用。
这项初步研究表明，肌醇可能是治疗未控制的GDM的一种安全的一线药物治疗方法。
